Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

CheckMate 218, a North American expanded access program (EAP), investigated nivolumab plus ipilimumab in patients with advanced melanoma. Safety and efficacy, including 2-year survival in clinically relevant patient subgroups, are reported. Eligible patients were aged ≥18 years with unresectable sta...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Melanoma Res
Hlavní autoři: Hodi, F. Stephen, Chapman, Paul B., Sznol, Mario, Lao, Christopher D., Gonzalez, Rene, Smylie, Michael, Daniels, Gregory A., Thompson, John A., Kudchadkar, Ragini, Sharfman, William, Atkins, Michael, Spigel, David R., Pavlick, Anna, Monzon, Jose, Kim, Kevin B., Ernst, Scott, Khushalani, Nikhil I., van Dijck, Wim, Lobo, Maurice, Hogg, David
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2020
Témata:
Original Articles: Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7757740/
https://ncbi.nlm.nih.gov/pubmed/33234846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000708
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky